Cargando…
Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases
Cardiac rhabdomyoma (CR) is the most common cardiac tumor in newborns. Approximately 75% of cases are associated with tuberous sclerosis complex. Although these tumors usually spontaneously regress after 2 years of age, they can be life-threatening when they obstruct major cardiac inflow or outflow...
Autores principales: | Chang, Jeng-Sheng, Chiou, Ping-Yun, Yao, Shu-Hui, Chou, I-Ching, Lin, Ching-Yuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628183/ https://www.ncbi.nlm.nih.gov/pubmed/28780710 http://dx.doi.org/10.1007/s00246-017-1688-4 |
Ejemplares similares
-
Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment
por: Bornaun, Helen, et al.
Publicado: (2016) -
Case report: Accelerated regression of giant cardiac rhabdomyomas in neonates with low dose everolimus
por: Hurtado-Sierra, Daniel, et al.
Publicado: (2023) -
Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019) -
Symptomatic improvement using everolimus in infants with cardiac rhabdomyoma
por: Dhulipudi, Bhargavi, et al.
Publicado: (2019) -
Efficacy of Everolimus Low-Dose Treatment for Cardiac Rhabdomyomas in Neonatal Tuberous Sclerosis: Case Report and Literature Review
por: Nespoli, Luisa Federica, et al.
Publicado: (2021)